Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
NCT06919081Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of Allogeneic bone marrow-derived mesenchymal stromal cell secretome in persistent corneal epithelial defect (PED), Corneal epithelial defect, sponsored by University of Illinois Chicago. Started Aug 2025; status: recruiting.
02
Drugs
Allogeneic bone marrow-derived mesenchymal stromal cell secretome
03
Conditions
persistent corneal epithelial defect (PED)Corneal epithelial defect
Beyond the preview
Go deeper on NCT06919081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919081.